Continuing its deleveraging plan subsequent to its $62B Shire acquisition, Takeda Pharmaceutical Company Limited (NYSE:TAK) has agreed to sell a portfolio of certain non-core over-the-counter (OTC) and prescription products sold in Europe and two manufacturing sites, one in Poland and the other in Denmark, to Danish outfit Orifarm Group for ~$670M.
The portfolio generated ~$230M in sales in fiscal 2018.
Source: Seeking Alpha